PMID- 33300587
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 2185-2243 (Electronic)
IS  - 0385-0005 (Linking)
VI  - 45
IP  - 4
DP  - 2020 Dec 20
TI  - Stability of HER2 Status by Dual-color in Situ Hybridization Before and After 
      Neoadjuvant Chemotherapy in Breast Cancer.
PG  - 176-181
AB  - OBJECTIVE: Trastuzumab may convert human epidermal growth factor receptor-2 
      (HER2)-positive primary breast tumors to HER2-negative tumors after chemotherapy. 
      This study determined whether trastuzumab increases the number of patients with 
      conversion to HER2-negative status and assessed the effect of neoadjuvant 
      chemotherapy. METHODS: We retrospectively reviewed 46 patients diagnosed with 
      HER2-overexpression in primary breast cancers at Tokai University Hospital, 
      receiving neoadjuvant chemotherapy by immunohistochemistry and fluorescence in 
      situ hybridization (FISH). Surgical specimens of patients achieving less than 
      pathological complete response (pCR) were verified for sufficient residual tissue 
      to evaluate post-treatment HER2 status by dual-color in situ hybridization 
      (DISH). RESULTS: pCR was achieved in 8 of the 46 (17.4%) patients. The residual 
      tumor was sufficient for a ssessing post-treatment HER2 status in 25 patients. 
      DISH of pretreatment specimens confirmed HER2 amplification prior to therapy. Of 
      the 25 HER2-positive patients, DISH revealed 3 were HER2 negative in pretreatment 
      specimens. No post-treatment tumors were HER2-negative according to DISH in 
      HER2-positive pre-treatment tumors. Among HER2-negative pretreatment tumors, 1 
      post-treatment tumor was HER2 positive and 2 had stable HER2 status. CONCLUSION: 
      HER2 status determined by DISH was stable between pretreatment breast tumors and 
      residual tumors. However, a small discrepancy regarding HER2 status determined by 
      immunohistochemistry and DISH existed.
FAU - Okamura, Takuho
AU  - Okamura T
FAU - Kumaki, Nobue
AU  - Kumaki N
FAU - Tsuda, Banri
AU  - Tsuda B
FAU - Niikura, Naoki
AU  - Niikura N
AD  - Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 
      143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. niikura@is.icc.u-tokai.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20201220
PL  - Japan
TA  - Tokai J Exp Clin Med
JT  - The Tokai journal of experimental and clinical medicine
JID - 7704186
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*genetics/pathology/*therapy
MH  - Female
MH  - Gene Expression/*drug effects
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - Male
MH  - Mastectomy
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Retrospective Studies
MH  - Trastuzumab/*pharmacology/*therapeutic use
MH  - Treatment Outcome
EDAT- 2020/12/11 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/12/10 08:39
PHST- 2020/07/03 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/12/10 08:39 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PST - epublish
SO  - Tokai J Exp Clin Med. 2020 Dec 20;45(4):176-181.